A combination regimen consisting of BRAF inhibitors—dabrafenib plus trametinib—was approved by the FDA for ATC-positive BRAFV600E mutation and resulted in significant tumor volume regression and 100% control of the locoregional spread [59]. The gene discussed is BRAF; the disease is neoplasm.